1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Neem's Hill AB

Neem's Hill AB

NEEMS-B.ST
Neem's Hill ABSE flagStockholm Stock Exchange
2.71
SEK
-0.05
- -
64.50MMarket Cap
Neem's Hill AB
NEEMS-B.ST
(Stockholm Stock Exchange)

Recent

price

2.71

P/E

ratio

- -

div

yld

- -

ROIC.AI

2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
0.01
- -
0.35
0.16
0.02
0.01
0.04
0.15
0.28
0.48
0.48
Revenue per Share
-0.02
-0.99
- -
-2.4
-3.62
-1.85
-1.84
-1.89
-1.13
-0.59
-0.32
-0.32
Basic EPS, GAAP
-0.05
0.48
- -
-2.57
-4.56
-1.64
-2.32
-1.65
-1.02
-0.57
-0.16
-0.2
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.03
0.5
- -
4.56
2.86
1.47
2.48
1.16
0.59
0.26
0.13
0.06
Book Value per Share
0.01
-1.24
- -
1.9
-0.63
-0.41
1.22
0.38
0.19
0.02
-0.02
-0.06
Tangible Book Value per Share
1
1
1
3
3
6
10
12
19
23
25
25
Basic Weighted Avg Shares
- -
- -
- -
1
1
- -
- -
- -
3
7
12
12
Sales/Revenue/Turnover
- -
-8,270.12
- -
-699.15
-2,153.06
-8,266.41
-34,851.02
-4,421.14
-717.12
-194.88
-52.61
-54.46
Operating Margin (%)
- -
- -
- -
1
2
2
3
3
3
2
2
2
Depreciation Expense
- -
-1
- -
-8
-12
-12
-18
-23
-21
-14
-8
-8
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
-8,498.88
- -
-693.88
-2,216.73
-8,903.82
-36,210.2
-4,808.88
-747.38
-208.91
-65.58
-66.21
Profit Margin (%)
- -
-1
- -
7
-2
-3
12
4
3
- -
-1
-2
Working Capital
- -
1
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
- -
1
- -
16
10
9
24
14
11
6
3
2
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-258.13
- -
-101.56
-95.55
-123.01
-107.04
-120
-168.57
-161.27
-175.78
-430.16
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
25
25
26
Market Capitalization
128
94
100

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
9
7
8
Cash, Cash Equivalents & STI
4
1
1
Accounts Receivable, Net
1
3
3
Inventories
3
3
3
Total Current Liabilities
10
9
9
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
0.76%
-46.72%
Free Cash Flow
- -
0.43%
-68.3%
Net Income, GAAP
- -
-0.64%
-41.27%
Sales/Revenue/Turnover
- -
303.82%
87.1%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1
2
1
2
7
2025
2
4
3
3
12
2026
3
3
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.18
-0.23
-0.14
-0.14
-0.59
2025
-0.14
-0.04
-0.05
-0.1
-0.32
2026
-0.06
-0.1
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
ClearPoint Neuro, Inc. (CLPT)
Health Logic Interactive Inc. (CHYPF)
Siemens Healthineers AG (SHL.DE)
IceCure Medical Ltd (ICCM)
CeriBell, Inc. (CBLL)
Beyond Air, Inc. (XAIR)
Business
Neem’s Hill AB is a medical technology company that develops and commercializes patented tumour-specific electroporation technology for cancer treatment in humans and animals; its core offerings include the IQwave™ platform, TSE-based treatment systems, advanced hardware and software, and related clinical and commercial support services for superficial solid tumours and other hard-to-treat cancers. The company operates through two business areas, Human Care and Animal Care, and focuses on cost-effective, tissue-preserving therapies that complement or reduce reliance on surgery, radiotherapy, and chemotherapy, with geographic emphasis on Sweden and international markets including India and selected regions in the Middle East, Asia, Southeast Asia, Africa, and veterinary markets across Europe and other regions. Founded in 2013 and headquartered in Lund, Sweden, Neem’s Hill AB was formerly Scandinavian ChemoTech AB and changed its name and trading ticker to reflect a broader strategic scope. Recent major developments include a strategic reorganization into separate Human Care and Animal Care business areas, a SEK 6 million growth loan to support commercial expansion, and a strategic partnership plus order from the University of Copenhagen’s veterinary hospitals to expand VQ Animal Care’s TSE treatment into companion animal and equine clinical settings. The company has also reported continued clinical progress in veterinary oncology, including publications and treatment outcomes supporting its Animal Care business, while maintaining its focus on patented TSE technology and broader commercialization of tumour-specific electroporation solutions.